{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-257347","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.859690+00:00","generated_at":"2026-05-17T01:25:03.031921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvalent Q3 net loss $122.4M; completes NDA for zidesamtinib; cash $943M into 2028","bullets":["Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC.","On track to report topline pivotal data for neladalkib in ALK-positive NSCLC by year-end 2025.","Cash, cash equivalents and marketable securities of $943.1M as of Sept 30, 2025; expected runway into 2028.","Q3 2025 net loss of $122.4M, R&D expenses $83.8M, G&A expenses $28.9M.","Presented preliminary data for neladalkib in ALK-positive solid tumors at ESMO and preclinical data for NVL-330 in HER2-altered NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-257347","json":"https://secwatch.observer/filing/0001193125-25-257347.json","markdown":"https://secwatch.observer/filing/0001193125-25-257347.md","text":"https://secwatch.observer/filing/0001193125-25-257347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000119312525257347/0001193125-25-257347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000119312525257347/nuvl-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:25:03.031921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}